Enasidenib Mesylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Enasidenib Mesylate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
45
Registered trials
56
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Enasidenib Mesylate can convert its Small molecule drug profile and IDH2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Enasidenib Mesylate (query alias: Enasidenib Mesylate) |
|---|---|
| Modality / target | Small molecule drug; IDH2; IDH2 inhibitors, Epigenetic drug |
| Highest global status | Approved |
| Originator | Celgene Corp. |
| Active developers | Bristol Myers Squibb Co., Celgene Corp., Celgene, Inc. |
The MCP disease footprint includes Acute Myeloid Leukemia, Immunoblastic Lymphadenopathy, CCUS Clonal Cytopenia of Undetermined Significance. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06672146 | Phase 2 | Recruiting | 93 | Minimal residual disease negative (MRDneg) complete remission (CR) rate |
| NCT06577441 | Phase 2 | Recruiting | 54 | Complete response (CR) rate |
| NCT06756308 | Phase 2 | Recruiting | 25 | response rate |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
MINE REGIMEN COMBINED WITH TARGETED AGENTS IN RELAPSED/REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: A PRELIMINARY EXPLORATORY RETROSPECTIVE STUDY INTEGRATED WITH NEXT-GENERATION SEQUENCING
Not Applicable; n=9; evaluation: Positive. Reported fields: ORR = 77.8 %
A Phase Ib/II, Single Center, Open-Label, Safety and Efficacy Study to Improve Anemia in Subjects on Enasidenib With Lower Risk Myelodysplastic Syndrome and Non-proliferative Chronic Myelomonocytic Leukemia Without an IDH2 Mutation
Phase 1/2; n=17; evaluation: not stated. Reported fields: Clinical Response: Hematological Improvement - Erythroid (HI-E) = 0 participants ; -; -
Multi-institutional retrospective study of IDH2-mutated cholangiocarcinoma.
Not Applicable; n=40; evaluation: Positive. Reported fields: -; OS = 16.3 Month ( 12.1 - 28.9)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Enasidenib Mesylate addresses Acute Myeloid Leukemia, Immunoblastic Lymphadenopathy, CCUS Clonal Cytopenia of Undetermined Significance. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| Agios and Royalty Pharma Announce $255 Million Purchase Agreement for IDHIFA® Royalty | Approved | US$255.0M stated total | |
| 2018-06-04 | MD Anderson will initiate a phase I clinical trial investigating the combination of Agios' ivosidenib or enasidenib with azacitidine for the treatment of acute myeloid leukemia (AML). | Approved | Financial terms not disclosed |
| 2010-04-15 | Celgene Corporation and Agios Pharmaceuticals Announce Global Strategic Collaboration to Advance Unique Science of Cancer Metabolism | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
